A new study from the University of Michigan Rogel Cancer Center has uncovered how specific mutations in the FOXA1 gene can both trigger prostate cancer and make it harder to treat. The research, recently published in Science, explains how these genetic changes affect cancer development and resistance to therapy.
What Is FOXA1 and Why It Matters
FOXA1 is a protein that helps control how cells respond to hormones like testosterone. It plays a key role in prostate cells, and mutations in this gene are found in 10–40% of prostate cancers. Until now, scientists didn’t fully understand how these mutations changed cancer behavior.
Dr. Arul Chinnaiyan and Dr. Abhijit Parolia led the study, using mouse models to study how different types of FOXA1 mutations work. Their research showed that these mutations don’t all act the same way — and that makes a big difference in how prostate cancer starts and how it responds to treatment.
Two Mutation Types, Two Different Effects
The researchers found that FOXA1 mutations fall into two major categories:
Class 1 mutations, which are more common in early-stage (primary) prostate cancer, work together with a damaged TP53 gene (a well-known cancer-related gene) to drive aggressive tumor growth. These tumors still depend on male hormones, which means they usually shrink when patients receive androgen deprivation therapy (ADT) — a standard treatment that lowers hormone levels.
Class 2 mutations are mostly seen in advanced, metastatic prostate cancer. These don’t start tumors on their own. Instead, they change the identity of prostate cells, helping the cancer resist hormone treatments. In effect, the cancer “learns” how to survive even when hormones are removed.
This is the first time scientists have clearly shown that FOXA1 mutations can actually start cancer in living animals — not just in lab-grown cells. “Our mouse models give us solid proof that FOXA1 is a true cancer-causing gene,” said Dr. Chinnaiyan.
New Clues for Better Treatments
The study builds on earlier work that identified three types of FOXA1 mutations. But now, researchers can explain exactly how each type affects cancer growth and therapy resistance.
Hormone therapy remains the main treatment for prostate cancer. While it works at first, many patients eventually become resistant — and that’s when the disease becomes much harder to treat.
“Until now, it’s been tough to model this hormone resistance in animals,” said Dr. Parolia. But with their new mouse models, they showed that Class 1 tumors stop growing without hormones, while Class 2 tumors rewire themselves to survive.
Class 2 mutations allow cancer cells to switch on hidden parts of DNA, which then activate genes that help the cancer fight off hormone-blocking drugs.
Why This Matters
This research not only shows how FOXA1 mutations help prostate cancer evolve, but also suggests that patients with different types of FOXA1 mutations may need different treatment strategies in the future.
By understanding these genetic details, scientists hope to design more personalized therapies — ones that target the specific mutation a patient has.
“This discovery gives us a deeper look at how prostate cancer grows and adapts,” said Dr. Chinnaiyan. “And it could lead to new ways to stop it.”
